sirw
doubt
benefit
lipidlow
drug
cardiovascular
morbid
mortal
howev
disput
conclus
peter
sever
colleagu
april
p
benefici
effect
atorvastatin
present
angloscandinavian
cardiac
outcom
triallipid
lower
arm
ascotlla
lar
lindholm
ola
samuelsson
report
accompani
commentari
p
addit
benefit
lipidlow
treatment
upon
antihypertens
treatment
rather
low
ascotlla
benefit
atorvastatin
signific
patient
diabet
leftventricular
hypertrophi
previou
vascular
diseas
among
women
placebo
even
nonsignificantli
better
result
atorvastatin
posit
result
atorvastatin
signific
patient
age
year
younger
without
renal
dysfunct
metabol
syndrom
disappoint
result
among
women
accord
find
antihypertens
lipidlow
treatment
prevent
heart
attack
trial
allhatllt
pravastatin
reduc
allcaus
mortal
myocardi
infarct
fatal
coronari
heart
diseas
one
explan
find
could
allhatllt
almost
particip
women
high
proport
patient
control
group
use
statin
ascot
investig
argu
number
event
among
women
particip
diabet
small
inadequ
power
studi
howev
doubt
use
lipidlow
treatment
popul
women
low
incid
cardiovascular
event
almost
patientyear
find
atorvastatin
effect
total
mortal
accord
result
previou
primari
prevent
studi
howev
effect
cardiovascular
mortal
would
expect
view
high
number
risk
factor
among
ascotlla
particip
ascotlla
stop
prematur
year
signific
reduct
mortal
could
shown
first
year
studi
decreas
trend
mortal
addit
even
nonsignific
trend
toward
disadvantag
atorvastatin
fatal
nonfat
heart
failur
peripher
arteri
diseas
develop
diabet
mellitu
renal
impair
reason
atorvastatin
show
similar
benefici
effect
simvastatin
pravastatin
might
found
low
dose
atorvastatin
use
ascotlla
higher
dose
might
shown
better
result
also
substanti
differ
biochem
structur
differ
statin
lovastatin
pravastatin
natur
statin
fungal
origin
wherea
simvastatin
semisynthet
deriv
lovastatin
atorvastatin
fluvastatin
fulli
synthet
statin
addit
cromwel
ziajka
found
longterm
use
atorvastatin
led
tachyphylaxi
decreas
respons
physiolog
activ
agent
result
increas
ldl
cholesterol
time
despit
optimum
treatment
contrast
statin
show
evid
tachyphylaxi
atorvastatin
offer
addit
benefit
antihypertens
treatment
reduct
fatal
nonfat
cardiovascular
event
women
patient
diabet
leftventricular
hypertrophi
previou
vascular
diseaseand
without
affect
mortal
dirk
devroey
receiv
travel
expens
merck
sharp
dohm
belgium
serv
consult
receiv
research
fund
novarti
belgium
bristolmy
squibb
belgium
pfizer
belgium
sponsor
research
meet
sira
common
observ
patient
sever
acut
respiratori
syndrom
sar
pronounc
lymphopenia
report
preval
glucocorticoid
profound
effect
circul
lymphocyt
may
involv
movement
intravascular
compart
glucocorticoid
also
use
therapeut
lymphoprolif
diseas
cytoleth
action
studi
lee
colleagu
use
steroid
may
account
decreas
trend
lymphocyt
count
day
treatment
booth
colleagu
use
steroid
patient
less
half
receiv
first
h
therefor
lymphopenia
report
booth
colleagu
may
associ
use
steroid
account
patient
certainli
lymphopenia
initi
present
critic
ill
accompani
activ
hypothalamicpituitaryadren
axi
result
increas
adrenocorticotrop
hormon
acth
cortisol
maintain
integr
vasculatur
modul
action
proinflammatori
antiinflammatori
cytokin
healthi
person
sever
stress
pituitari
acth
easili
caus
adren
cortex
releas
mg
per
day
cortisol
equival
dosag
methylprednisolon
use
lee
colleagu
drive
lymphocyt
peripher
circul
therefor
lymphopenia
seen
sar
patient
indic
integr
statu
hypothalamicpituitaryadren
axi
importantli
patient
without
lymphopenia
adren
insuffici
answer
question
need
address
urgent
may
bear
whether
use
glucocorticoid
treatment
sar
thompson
provid
help
review
glucocorticoid
acut
lung
injuri
